The efficacy and safety of Camrelizumab combined with Docetaxel and Nedaplatin in Neoadjuvant therapy for esophageal squamous cell carcinoma: A single-arm, exploratory, multicenter Phase II clinical study
Latest Information Update: 04 Aug 2020
At a glance
- Drugs Camrelizumab (Primary) ; Docetaxel (Primary) ; Nedaplatin (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 04 Aug 2020 New trial record